参考文献

1.付小兵，王正国，吴祖泽.再生医学基础与临床.北京:人民卫生出版社，2014.

2.庞希宁，付小兵.干细胞与再生医学.北京：人民卫生出版社，2014.

3.中国科学院.中国学科发展战略——再生医学.北京:科学出版社，2015.

4.付小兵，王正国，吴祖泽.再生医学原理与实践.上海：上海科学技术出版社，2008.

5.裴雪涛.再生医学理论与技术.北京：科学出版社，2010.

6.DavidL.Stocum.再生生物学与再生医学.庞希宁，付小兵，译.北京：科学出版社，2012.

7.王正国.中国再生医学研究现状与展望.中国实用内科杂志，2012，32（8）：561-564.

8.付小兵.中国再生医学研究：需求与转化应用.解放军杂志，2012，37（3）：169-171.

9.戴尅戎.再生医学与转化研究.中华关节外科杂志（电子版），2011，5（1）：68-71.

10.江虎军，孙瑞娟，裴端卿，等.干细胞与再生医学的发展现状及重要意义.中国科学院院刊，2011，26（2）:174-178.

11.董尔丹，胡海，洪微.浅析转化医学与医学实践.科学通讯，2013，58（1）:53-62.

12.袁宝珠.干细胞研究产业发展及监管科学现状.中国药事，2014，28（12）:1380-1384.

13.袁宝珠.治疗性干细胞产品的相关风险因素.中国生物制品学杂志，2013，26（5）:736-739.

14.Choi DW.Bench to bedside:The glutamate connection.Science，1992，258（5080）:241-243.

15.Geraghty J.Adenomatous polyposis coli and translational medicine.Lancet，1996，348（9025）:422.

16.Lean ME，Mann JI，Hoek JA，et al.Translational research.BMJ，2008，337（7672）:a863.

17.Woolf SH.The meaning of translational research and why it matters.JAMA，2008，299（2）:211-213.18.Choi DW.Bench to bedside:The glutamate connection.Science，1992，258（5080）:241-243.

19.Geraghty J.Adenomatous polyposis coli and translational medicine.Lancet，1996，348（9025）:422.

20.Sanders S.Regenerative Medicine in China.Science，2012，336（6080）:497.

21.Orlic D，Kajstura J，Chimenti S，et al.Bone marrow cells regenerate infracted myocardium.Nature，2001，410（6829）:701-705.

22.Kocher AA，Schuster MD，Szabolcs MJ，et al.Neovascularization of ischemic myocardium by human bone marrow derived angioblasts prevents cardiomyocyte apoptosis，reduces remodeling and improves cardiac function.Nat Med，2001，7（4）:430-436.

23.Anversa P，Nadal-Ginard B.Myocyte renewal and ventricular remodeling.Nature，2002，415（6868）:240-243.

24.Belteamin AP，Urbanek K，Kajstura J，et a.Evidence That Human Cardiac Myocytes Divide after Myocardial Infarction.N Engl J Med，2001，344（23）:1750-1757.

25.Verfaillie Catherine M.Pluripotency of mesenchymal stem cells derived from adult marrow.Nature，2002，418（6893）:41-49.

26.Mason C，Manzotti E.Stem cell nations working together for a stem cell world.Regenerative Medicine，2015，5（1）:1.

27.Mcmahon DS，Thorsteinsdóttir H，Singer PA，et al.Cultivating regenerative medicine innovation in China.Regenerative Medicine，2010，5（1）:35-44.

28.Williams DA.Keating A.Enhancing research in regenerative medicine.Blood，2010，116（6）:866-867.

29.Esteban MA，Wang T，Qin B，et al.Vitamin C Enhances the Generation of Mouse and Human Induced Pluripotent Stem Cells.Cell Stem Cell，2010，6（1）:71-79.

30.Li R，Liang J，Ni S，et al.A Mesenchymal-to-Epithelial Transition Initiates and Is Required for the Nuclear Reprogramming of Mouse Fibroblasts.Cell Stem Cell，2010，7（1）:51-63.

31.Zhao Y，Yin X，Qin H，et al.Two supporting factors greatly improve the efficiency of human iPSC generation.Cell Stem Cell，2008，3（5）:475-479.

32.Zou K，Yuan Z，Yang Z，et al.Production of offspring from a germline stem cell line derived from neonatal ovaries.Nat Cell Biol，2009，11（5）:631-636.

33.Zhao XY，Li W，Lv Z et al.iPS cells produce viable mice through tetraploid complementation.China Basic Science，2009，461（7260）:86-90.

34.Takahashi K，Tanabe K，Ohnuki M，et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors.Cell，2007，131（5）:861-872.

35.Yu J，Vodyanik MA，Smuga-Otto K，et al.Induced pluripotent stem cell lines derived from human somatic cells，Science，2007，318（5858）:1917-1920.

36.Zhu WW，Yu Y，Zhou Q，et al.The development and expectation of stem cell research with new pattern.Bulletin of The Chinese Academy of Sciences，2009，24（3）:284-289.

37.Liu FF，Hou ZL.Research progress and application prospect of induced pluripotent stem cells.Journal of Clinical Rehabilitative Tissue Engineering Research，2014，18（1）:149-154.

38.Takahashi K，Tanabe K，Ohnuki M，et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors.Cell，2007，131（5）:861-872.

39.moue H，Yamanaka S.The use of induced pluripotent stem cells in drug development.Clin Pharmacol Ther，2011，89（5）:655-661.

40.Wu SM，Hochedlinger K.Harnessing the potential of induced pluripotent stem cells for regenerative medicine.Nat Cell Biol，2011，13（5）:497-505.

41.Wang M，Lin J，Sun CK，et al.Information analysis of iPSCs and its translational medicine.Basic&Clinical Medicine，2013，33（12）:1554-1559.

42.Rosemann A.Modalities of value，exchange，solidarity:the social life of stem cells in China.New Genetics and Society，2011，30（2）:181-192.

43.Tang PH.Controversy on adult stem-cell plasticity and rules governing the use of fetal tissue in China.Journal of Laboratory and Clinical Medicine，2004，143（4）:199-200.

44.Salter B，Cooper M，Dickins A.China and the global stem cell bioeconomy:an emerging political strategy.Regenerative Medicine，2006，1（5）:671-683.

45.Qiu J.Injection of hope through China’s stem-cell therapies.Lancet Neurology，2008，7（2）:122-123.

46.Liao LM，Zhao RC.An overview of stem cell-based clinical trials in China.Stem Cells and Development，2008，17（4）:613-618.

47.Dai JW，Gao SR.Stem cell research is coming of age in China.Journal of Genetics And Genomics，2010，37（7）:413-413.

48.Saltce B，Cooper M，Dickins A，et al.Britain and India stem cell strategy.Biotech World，2007，1（2）:78-83.

49.Thomas KE，Moon LDF.Will stem cell therapies be safe and effective for treating spinal cord injuries.BritishMedical Bulletin，2011，98（1）:127-142.

50.Jiao JW.Embryonic and adult neural stem cell research in China.Science China-Life Sciences，2010，53（3）:338-341.

51.Chen Tao，Qian Wan-qiang.Comparative analysis of stem cell research and industry development between china and foreign countries.Forum Sci Technol China，2011，10（10）:150-153，160.